⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925524 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL22833798 | 0.80 | KDM5A (0.40) | — | |
| SCHEMBL27523137 | 0.76 | — | — | |
| SCHEMBL9729220 | 0.76 | TBXAS1 (0.46) | — | |
| SCHEMBL24655835 | 0.74 | — | — | |
| SCHEMBL24329576 | 0.73 | — | — | |
| SCHEMBL27772454 | 0.73 | — | — | |
| SCHEMBL24655834 | 0.73 | KDM5A (0.44) | — | |
| SCHEMBL24655851 | 0.73 | CPB2 (0.37) | — | |
| SCHEMBL16964094 | 0.73 | TDP1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409331-B | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-112409331-A | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10174067-B2 | Type of cytidine derivative and application thereof | CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170355726-A1 | NEW TYPE OF CYTIDINE DERIVATIVE AND APPLICATION THEREOF | CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD (CN) | 2017-12-14 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| CN-105273724-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | CHI MEI CORP | 2016-01-27 | — | — | CN | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| EP-2663553-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012030944-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |